These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9046125)

  • 21. [Mumps in Poland in 2004].
    Stefanoff P
    Przegl Epidemiol; 2006; 60(3):389-92. PubMed ID: 17249158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outbreak of mumps in a vaccinated child population: a question of vaccine failure?
    Vandermeulen C; Roelants M; Vermoere M; Roseeuw K; Goubau P; Hoppenbrouwers K
    Vaccine; 2004 Jul; 22(21-22):2713-6. PubMed ID: 15246601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 26. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine.
    American Academy of Pediatrics. Committee on Infectious Diseases
    Pediatrics; 1998 Jan; 101(1 Pt 1):129-33. PubMed ID: 11345975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mumps in Poland since 1990 to 2003; epidemiology and antibody prevalence.
    Janaszek-Seydlitz W; Bucholc B; Gorska P; Slusarczyk J
    Vaccine; 2005 Apr; 23(21):2711-6. PubMed ID: 15780717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mumps in Poland in 2003].
    Rosińska M
    Przegl Epidemiol; 2005; 59(2):209-13. PubMed ID: 16190522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent resurgence of mumps in the United States.
    Dayan GH; Quinlisk MP; Parker AA; Barskey AE; Harris ML; Schwartz JM; Hunt K; Finley CG; Leschinsky DP; O'Keefe AL; Clayton J; Kightlinger LK; Dietle EG; Berg J; Kenyon CL; Goldstein ST; Stokley SK; Redd SB; Rota PA; Rota J; Bi D; Roush SW; Bridges CB; Santibanez TA; Parashar U; Bellini WJ; Seward JF
    N Engl J Med; 2008 Apr; 358(15):1580-9. PubMed ID: 18403766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population.
    Ong G; Goh KT; Ma S; Chew SK
    J Infect; 2005 Nov; 51(4):294-8. PubMed ID: 16291282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students--Iowa, 2006.
    Marin M; Quinlisk P; Shimabukuro T; Sawhney C; Brown C; Lebaron CW
    Vaccine; 2008 Jul; 26(29-30):3601-7. PubMed ID: 18539365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mumps: a year of enhanced surveillance in Catalonia, Spain.
    Dominguez A; Oviedo M; Torner N; Carmona G; Costa J; Caylà J; Sala MR; Barrabeig I; Camps N; Minguell S; Alvarez J; Godoy P; Jansà JM;
    Vaccine; 2009 May; 27(25-26):3492-5. PubMed ID: 19460603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
    Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B
    Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mumps in Poland in 2007].
    Paradowska-Stankiewicz I; Orlíková H; Rudowska J
    Przegl Epidemiol; 2009; 63(2):173-5. PubMed ID: 19799239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing incidence of mumps in Scotland: options for reducing transmission.
    Donaghy M; Cameron JC; Friederichs V
    J Clin Virol; 2006 Feb; 35(2):121-9. PubMed ID: 16289903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 24-year review on the epidemiology and control of measles in Singapore, 1981-2004.
    Ong G; Hoon HB; Ong A; Chua LT; Kai CS; Tai GK
    Southeast Asian J Trop Med Public Health; 2006 Jan; 37(1):96-101. PubMed ID: 16771219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.
    McIntyre P; Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M
    Commun Dis Intell; 2000 Jun; Suppl():v-83. PubMed ID: 12049363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mumps and mumps vaccine: a global review.
    Galazka AM; Robertson SE; Kraigher A
    Bull World Health Organ; 1999; 77(1):3-14. PubMed ID: 10063655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.